This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Up to this point, cannabis stocks have been trendy and red-hot thanks to global progress toward regulations that legalize weed. But, those same trendy and red-hot cannabis stocks have failed to gain mainstream traction because the regulation picture globally remains a hot mess, full of delays and complicated nuances. As such, cannabis stocks had their day in the sun, but that day is over. Most of them have traded sideways for the better part of 2018.
CVSI TWMJF ACB GWPH WEED ACBFF CGC GWP
12h investorplace - 2
To be honest, I’m not entirely thrilled about investing in marijuana stocks at the moment. Movement toward legalization at the state level in the United States and at the national level in Canada has sent a number of pot stocks soaring. But not all marijuana stocks necessarily are going to be winners. The sector may not be an outright bubble — yet — but there’s certainly a case that rising marijuana-related optimism has lifted all boats, including several that have some leaks.
STZ.B CRON DTK STZ CGC TLRY TAP TWMJF GWPH MRK WEED NVS PFE GWP SMG
GW Pharmaceuticals has finally revealed the price of its cannabis-based epilepsy drug Epidiolex. The medication, which is expected to be available by early fall, will have a $32,500 price tag.
Chicago, IL – August 9, 2018 – Zacks Equity Research highlights Micron (MU - Free Report) as the Bull of the Day, Ultra Clean Holdings (UCTT - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis onThe Scotts Miracle-Gro Company (SMG - Free Report) , GW Pharmaceuticals (GWPH - Free Report) , Innovative Industrial Properties (IIPR - Free Report) , Molson Coors (TAP - Free Report) and Constellation Brands (STZ - Free Report) .
LRCX STZ.B UCTI CXO STZ TRTN MPC CGC GLUU TWMJF IIPR ROSEU TPX.B WEED HEAR GWP FG UCTT SMG ROSE
GW Pharmaceuticals PLC said it plans to charge about $32,500 per patient annually in the U.S. for its new treatment for rare forms of epilepsy, the first prescription drug derived from the marijuana plant.
VANCOUVER, British Columbia, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that Clearstream Banking, a major central securities depository based in Frankfurt, Germany, which announced on June 25, 2018 that it would stop dealing with all North American cannabis stocks, has revised its decision to now solely deal with companies focused on medical cannabis such as Veritas.
TWMJF ACB VRT WEED ACBFF VRTHF CGC GWP
2018-08-08 investorplace - 1
GW Pharmaceuticals NASDAQ:GWPH) stock was flat late in the day Tuesday as the company reported its latest quarterly earnings results, which saw its loss widen year-over-year, while revenue increased.
KELOWNA, BC / ACCESSWIRE / August 1, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to report significant bioavailability results from its randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBD TM - a proprietary, DehydraTECH™ powered, cannabidiol ("CBD") fortified hemp oil capsule developed by Lexaria.
LXX GWP LXRP
TORONTO, July 25, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (to be renamed Sol Global Investments Corp.) (the "Company" or “Scythian”) (TSXV:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl:SCCYF) today announced that its Chief Medical Officer, Professor Michael Barnes, is rapidly expanding his international strategy and influential reach.
LONDON, July 23, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 August, 2018 its third quarter financial results for the period ending 30 June, 2018. GW will also host a conference call the same day at 4:30 p.
2018-08-20 - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
2018-08-20 - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2018-08-20 - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...